Biodistribution of the Bombesin Receptor-Targeted Radiopharmaceutical Precursor BBN/C1-C2 in a Prostate Cancer Model.

E A Beloborodov, E V Iurova, D R Dolgova, A A Ermakova, D E Sugak, A N Fomin, Y V Saenko

Abstract read

In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

E A BeloborodovResearcher, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

E V IurovaJunior Researcher, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

D R DolgovaPhD, Senior Researcher, Laboratory of Molecular and Cellular Biology, S.P. Kapitsa National Research Institute of Technology; Director of the Research Medical and Biological Center; Associate Professor, Department of Physiology and Pathophysiology; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

A A ErmakovaResearch Assistant, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

D E SugakJunior Researcher, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

A N FominPhD, Senior Researcher, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

Y V SaenkoDSc, Leading Researcher, Laboratory of Research and Development of Peptide Drugs and Vaccines, S.P. Kapitsa Technological Research Institute; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, Russia, 432017.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor expressed in the central nervous system, the gastrointestinal tract, the pancreas, and the adrenal cortical tissue regulating their physiological functions. In addition to normal tissues, GRPR is overexpressed in many solid cancers. At present, several radiolabeled ligands targeting GRPR have been introduced into clinical practice for cancer diagnostics and radioligand therapy. However, there were found the high uptake of radiopharmaceuticals in normal organs and low bioavailability of the drugs caused by their stability. Therefore, GRPR radioantagonists with improved proteolytic stability and longer residence time in tumor foci with low uptake in non-target organs are currently being sought to improve the therapeutic efficacy. Materials and Methods: The study analyzed the biodistribution of Cy7.5-labeled BBN/C1-C2 peptide based on bombesin and knottin U5-Sth1a and produced using solid-phase peptide synthesis. The investigation was carried out on a mouse model Nu/Nu with a prostate cancer solid tumor (PC-3 culture) transplanted into the right side, expressing GRPR, using real-time surface fluorescent imaging on days 2 and 5 after intravenous administration of the molecules under study. Results: The biodistribution analysis showed the selective binding of the BBN/C1-C2 molecule to a tumor, as well as its holding power on the tumor surface for up to 5 days without internalization into cells with low accumulation in normal organs and tissues. Conclusion: We managed to obtain a stable molecule; however, U5-Sth1a toxin tropic to ion channels was used as a scaffold, so the resulting molecule retained the domain responsible for attaching to the target channel and typical for knottin. In the future, when using the molecule as a ligand for radiotherapy, it can have a negative effect on the patient's heart due to the supplementary radiation load. In this regard, the BBN/C1-C2 molecule requires the extension study.

Indexed as

BombesinProstatic NeoplasmsRadiopharmaceuticalsReceptors, BombesinAnimalsCell Line, TumorHumansMaleMiceTissue DistributionBombesinRadiopharmaceuticalsReceptors, Bombesinbombesinbombesin receptorknottinpeptide toxintargeted therapy

Identifiers

PMID41684873

DOI10.17691/stm2025.17.6.03

PMCPMC12892846

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.